Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases
- 1 February 2019
- journal article
- review article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 17 (3) , 370-379
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel DiseaseAmerican Journal of Epidemiology, 2013
- Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort StudyPLOS ONE, 2013
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ RegistryAmerican Journal of Gastroenterology, 2012
- Association of Crohn’s Disease, Thiopurines, and Primary Epstein-Barr Virus Infection with Hemophagocytic LymphohistiocytosisThe Journal of Pediatrics, 2011
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Review article: explaining risks of inflammatory bowel disease therapy to patientsAlimentary Pharmacology & Therapeutics, 2010
- Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?Risk Analysis, 2008
- Mortality by Medication Use Among Patients With Inflammatory Bowel Disease, 1996–2003Gastroenterology, 2007
- Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2006